TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract

Xiaoyan Wang, Antonio Lopez-Beltran, Adeboye O. Osunkoya, Mingsheng Wang, Shaobo Zhang, Darrell Davidson, Robert Emerson, Sean R. Williamson, Puay Hoon Tan, Hristos Kaimakliotis, Lee Ann Baldridge, Gregory T. MacLennan, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalArticle

6 Scopus citations


Aim: To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma. Methods & results: TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery. Conclusion: Sarcomatoid carcinoma of the upper urinary tract is an aggressive tumor and the presence of TERT mutation may portend poor prognosis.

Original languageEnglish (US)
Pages (from-to)705-714
Number of pages10
JournalFuture Oncology
Issue number8
StatePublished - Apr 1 2017



  • biomarkers
  • bladder
  • GATA3
  • sarcomatoid urothelial carcinoma
  • TERT promoter mutation
  • upper urinary tract
  • ureter

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wang, X., Lopez-Beltran, A., Osunkoya, A. O., Wang, M., Zhang, S., Davidson, D., Emerson, R., Williamson, S. R., Tan, P. H., Kaimakliotis, H., Baldridge, L. A., MacLennan, G. T., Montironi, R., & Cheng, L. (2017). TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncology, 13(8), 705-714. https://doi.org/10.2217/fon-2016-0414